Trial Outcomes & Findings for Use of Levemir® Improves Metabolic and Clinical Status in Cystic Fibrosis-related Diabetes (CFRD) (NCT NCT00639626)
NCT ID: NCT00639626
Last Updated: 2018-04-12
Results Overview
TERMINATED
PHASE2/PHASE3
6 participants
6 months
2018-04-12
Participant Flow
PI left institution suddenly in 2010 and studies were closed. Study records for participants cannot be located and possibly have been destroyed.
Participant milestones
| Measure |
Levemir
insulin detemir \[rDNA origin\] injection: Starting dose of 0.1-0.3 units/kg/day in a once daily subcutaneous injection.
|
|---|---|
|
Overall Study
STARTED
|
0
|
|
Overall Study
COMPLETED
|
0
|
|
Overall Study
NOT COMPLETED
|
0
|
Reasons for withdrawal
Withdrawal data not reported
Baseline Characteristics
Use of Levemir® Improves Metabolic and Clinical Status in Cystic Fibrosis-related Diabetes (CFRD)
Baseline characteristics by cohort
Baseline data not reported
PRIMARY outcome
Timeframe: 6 monthsPopulation: PI left institution suddenly in 2010 and studies were closed. Study records for participants cannot be located and possibly have been destroyed.
Outcome measures
Outcome data not reported
SECONDARY outcome
Timeframe: 6 monthsPopulation: PI left institution suddenly in 2010 and studies were closed. Study records for participants cannot be located and possibly have been destroyed.
Outcome measures
Outcome data not reported
Adverse Events
Levemir
Serious adverse events
Adverse event data not reported
Other adverse events
Adverse event data not reported
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place